| 1. |
- Bergh Thorén, Fredrik, 1976, et al.
(författare)
-
Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
- 2009
-
Ingår i: Expert opinion on biological therapy. - : Informa Healthcare. - 1744-7682 .- 1471-2598. ; 9:9, s. 1217-23
-
Forskningsöversikt (refereegranskat)abstract
- Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Although most patients achieve complete remission (CR) after chemotherapy, the majority suffer from subsequent leukemic relapse, which is associated with poor long-term survival. Thus, new therapies to maintain CR are highly warranted. After the completion of chemotherapy, AML patients have a minimal burden of leukemic cells, which are reportedly susceptible to cytotoxic lymphocytes such as NK cells and T cells. A therapy that boosts the function of these effector cells therefore has the potential to eradicate the malignant clone in AML and prevent relapse, Here, we briefly review the literature on the role of the immune system in AML and introduce the rationale for the use of histamine dihydrochloride (HDC) in conjuction with low-dose IL-2 as relapse-preventive immunotherapy for this disease.
|
|
| 2. |
- Berglund, S., et al.
(författare)
-
Advances in umbilical cord blood cell therapy : the present and the future
- 2017
-
Ingår i: Expert Opinion on Biological Therapy. - : Taylor & Francis. - 1471-2598 .- 1744-7682. ; 17:6, s. 691-699
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: Umbilical cord blood (UCB), previously seen as medical waste, is increasingly recognized as a valuable source of cells for therapeutic use. The best-known application is in hematopoietic stem cell transplantation (HSCT), where UCB has become an increasingly important graft source in the 28 years since the first umbilical cord blood transplantation (UCBT) was performed. Recently, UCB has been increasingly investigated as a putative source for adoptive cell therapy. Areas covered: This review covers the advances in umbilical cord blood transplantation (UCBT) to overcome the limitation regarding cellular dose, immunological naivety and additional cell doses such as DLI. It also provides an overview regarding the progress in adoptive cellular therapy using UCB. Expert opinion: UCB has been established as an important source of stem cells for HSCT. Successful strategies to overcome the limitations of UCBT, such as the limited cell numbers and naivety of the cells, are being developed, including novel methods to perform in vitro expansion of progenitor cells, and to improve their homing to the bone marrow. Promising early clinical trials of adoptive therapies with UCB cells, including non-immunological cells, are currently performed for viral infections, malignant diseases and in regenerative medicine.
|
|
| 3. |
|
|
| 4. |
- Borrebaeck, Carl
(författare)
-
Antibody microarray-based oncoproteomics
- 2006
-
Ingår i: Expert Opinion on Biological Therapy. - : Informa Healthcare. - 1471-2598 .- 1744-7682. ; 6:8, s. 833-838
-
Tidskriftsartikel (refereegranskat)abstract
- The driving force behind oncoproteomics is the belief that certain protein signatures or patterns exist that are associated with a particular malignancy. if so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. The technological challenges to achieve these goals are significant, as the human proteome is not defined. No general methodological approach exists today, and human cancer can, furthermore, be divided into several disease subgroups. One potential solution to finding cancer-associated protein signatures is the emerging technology of affinity proteomics. This approach addresses some of the shortcomings of traditional proteomics and combines it with the power of microarrays. The present review focuses on the role of antibody microarrays in oncoproteomics and its potential to provide a truly proteome-wide analytical approach.
|
|
| 5. |
- Brännström, Mats, 1958
(författare)
-
Womb transplants with live births: an update and the future
- 2017
-
Ingår i: Expert Opinion on Biological Therapy. - : Informa UK Limited. - 1471-2598 .- 1744-7682. ; 17:9, s. 1105-1112
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Absolute uterine factor infertility, with a uterine absence or presence of a nonfunctional uterus, has during the last decades been the only remaining, major group of female infertility. Uterus transplantation (UTx) has now emerged as the first therapy for these women that have traditionally been regarded as unconditionally infertile.Areas covered: This review summarizes the research preparations in several experimental animal species that paved the way for the clinical introduction of UTx. The article also describes the human UTx attempts that have been reported up until today and the several live births that have occurred after the initial UTx baby was born in 2014. Future developments in human UTx and efforts to create a bioengineered uterus are also discussed.Expert opinion: UTx has already at this early phase of experimental introduction in the human setting proved to be a highly effective treatment for absolute uterine factor infertility. The UTx procedure has now been introduced at several centers worldwide within clinical research studies and with variations in techniques. The outcome and data from these studies will further optimize the UTx procedure to become a safe and highly effective infertility treatment.
|
|
| 6. |
- Di Giuseppe, D., et al.
(författare)
-
Uptake of rheumatology biosimilars in the absence of forced switching
- 2018
-
Ingår i: Expert Opinion on Biological Therapy. - : Informa UK Limited. - 1471-2598 .- 1744-7682. ; 18:5, s. 499-504
-
Tidskriftsartikel (refereegranskat)abstract
- Background: To describe the uptake and system-level effects of the introduction of biosimilars in a setting without forced switching.Research design and methods: We used data from the Swedish Rheumatology Quality register from start of marketing of infliximab (Remsima (R) and Inflectra (R)) and etanercept (Benepali (R)) biosimilars until 31 December 2016. We compared users of each originator-product and its biosimilar(s) by line of treatment: bDMARD-naive patients, non-medical switchers (vs. matched patients remaining on originator), and patients switching from a previous bDMARD of another type.Results: From the start of marketing 1343 patients started an infliximab biosimilar (22 months) and 2691 started etanercept (9months). Overall, the introduction of these biosimilars resulted in an increase of the total number of ongoing infliximab and etanercept treatments (originator + biosimilar) . At the end of the study period, biosimilars accounted for 31% of all infliximab treatments and 31% of all etanercept-treated patients. For each line of therapy, we noted only small differences in patient characteristics between those starting the originator product vs. its biosimilar(s).Conclusions: Introduction of biosimilars have effects beyond replacement of the originator product, in terms of an increased rate of bDMARD initiation. Selection to non-medical switching displayed no particular disease- or patient-characteristics.
|
|
| 7. |
|
|
| 8. |
- Enell Smith, Karin, et al.
(författare)
-
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
- 2021
-
Ingår i: Expert Opinion on Biological Therapy. - : Informa UK Limited. - 1471-2598 .- 1744-7682. ; 21:12, s. 1635-1646
-
Forskningsöversikt (refereegranskat)abstract
- Introduction: CD40 signaling activates dendritic cells leading to improved T cell priming against tumor antigens. CD40 agonism expands the tumor-specific T cell repertoire and has the potential to increase the fraction of patients that respond to established immunotherapies. Areas covered: This article reviews current as well as emerging CD40 agonist therapies with a focus on antibody-based therapies, including next generation bispecific CD40 agonists. The scientific rationale for different design criteria, binding epitopes, and formats are discussed. Expert opinion: The ability of CD40 agonists to activate dendritic cells and enhance antigen cross-presentation to CD8+ T cells provides an opportunity to elevate response rates of cancer immunotherapies. While there are many challenges left to address, including optimal dose regimen, CD40 agonist profile, combination partners and indications, we are confident that CD40 agonists will play an important role in the challenging task of reprogramming the immune system to fight cancer.
|
|
| 9. |
- Fishman, JM, et al.
(författare)
-
Airway tissue engineering
- 2011
-
Ingår i: Expert opinion on biological therapy. - : Informa Healthcare. - 1744-7682 .- 1471-2598. ; 11:12, s. 1623-1635
-
Tidskriftsartikel (refereegranskat)
|
|
| 10. |
|
|
